Remdesivir’s controversial cost, early vaccine data, and AI at the end of life – STAT

Whats a fair price for remdesivir? How do we know whether vaccines work? And does AI have a place in end-of-life care?

We discuss all that and more this week on The Readout LOUD, STATs biotech podcast. First, we dig into the long-awaited price for Gilead Sciences Covid-19 treatment and break down the disparate reactions from lawmakers, activists, and Wall Street analysts. Then, STATs Matthew Herper joins us to discuss some of the first detailed data on a potential vaccine for the novel coronavirus. Finally, we talk about a new use for AI: nudging clinicians to broach delicate conversations with patients about their end-of-life goals and wishes.

For more on what we cover, heres the remdesivir news; heres more on the vaccine data; heres the story on AI; and heres the latest in STATs coronavirus coverage.

advertisement

Well be back next Thursday evening and every Thursday evening so be sure to sign up onApple Podcasts,Stitcher,Google Play, or wherever you get your podcasts.

And if you have any feedback for us topics to cover, guests to invite, vocal tics to cease you can emailreadoutloud@statnews.com.

advertisement

Interested in sponsoring a future episode of The Readout LOUD? Email us atmarketing@statnews.com.

See the rest here:

Remdesivir's controversial cost, early vaccine data, and AI at the end of life - STAT